Corporate Symposia
Corporate Symposium (CS01) | Servier*
IDH Inhibition in Clinical Practice: Addressing Remaining Questions in Glioma
Friday, September 25 | 13:45 - 14:45 hrs | Sinopoli Hall
| 13:45 – 13:48 | Welcome |
Giuseppe Minniti – Co-Chair | |
| 13:48 – 13:58 | Unravelling the Complexity of Gliomagenesis |
Luis Nicolas Gonzalez Castro - Speaker | |
| 13:58 – 14:13 | From IDH Biology to Clinical Outcomes: INDIGO in Daily Practice |
Patrick Roth – Speaker | |
| 14:13 – 14:33 | How to manage and follow-up challenging mIDH Glioma Patients? |
Anna Berghoff - Speaker | |
| 14:33 – 14:45 | Q&A and Take Home Messages |
Corporate Symposium (CS02) | Oxford Nanopore Technologies*
Friday, September 25 | 13:45- 14:45 hrs | Petrassi Hall
Detailed programme following soon.
Corporate Symposium (CS03) | Merck Healthcare*
CARE FOR RARE: Navigating treatment approaches in NF1-associated plexiform neurofibroma
Saturday, September 26 | 14:15 - 14:45 hrs | Petrassi Hall
| 14:15 – 14:20 | Welcome and Introduction to NF1-PN |
Angela Mastronuzzi – Chair | |
| 14:20 – 14:30 | Case-based journey through the treatment algorithm: Evaluating our options; individualising our approach |
Said Farschtschi - Speaker | |
| 14:30 – 14:40 | Managing symptomatic, inoperable NF1-PN: What do the data tell us? |
Timothy Gershon – Speaker | |
| 14:40 – 14:45 | Practical Panel discussion & Q&A |
All | |
| 14:45 | Closing |
Angela Mastronuzzi - Chair | |
Corporate Symposium (CS04) | Servier
The Hidden Burden of Glioma Patients Revealed By Real World Data
Saturday, September 26 | 13:45 - 14:15 hrs | Theatre Studio
| 13:45 – 13:50 | Introduction: Discussing Integration of Patient Choice |
Roberta Ruda, Helen Bulbeck | |
| 13:50 – 14:00 | The Impact of Glioma on Daily Life and the Household |
Jane Skjøth-Rasmussen - Speaker | |
| 14:00 – 14:10 | Amplifying Patient Voice in Registries Through Digital |
Maria Vieito – Speaker | |
| 14:10 – 14:15 | What the Data Doesn't Tell us: The Patient Advocacy |
Helen Bulbeck - Speaker | |